April 22, 2016
Currently, there is some availability of generic divalproex.
According to information posted by Teva Canada Limited on drugshortages.ca, shipments of Teva-Divalproex tablets were expected to be sent to wholesalers the week of April 4 (250mg) and the week of April 18 (500mg). There has been no recent resupply of the 125mg Teva-Divalproex tablets, the estimated resupply date is May 31.
Apotex provided new updates on April 21. They are beginning to resupply Apo-Divalproex, starting with the 500mg tablets. Some inventory of this strength tablet is expected to ship to wholesalers on April 22. The estimated resupply dates for Apo-Divalproex are May 9 (500mg), May 31 (250mg) and July 31 (125mg).
Epival is expected to remain in shortage for the coming months. A recent update from BGP Pharma on drugshortages.ca indicates the estimated resupply dates for Epival are June 24 (500mg), July 15 (250mg) and August 5 (125mg).
Please note that the estimated resupply dates on drugshortages.ca are when the drug should be ready to ship from the manufacturer to distributors, add ~ 7 days transition time to get an estimate of availability in community pharmacies.
Pharmacists who are out-of-stock and have exhausted all avenues to obtain divalproex can contact Teva Canada customer service to request an emergency allocation.
Contact information for emergency requests:
Teva Canada Limited
tel (416) 291-9595
March 18, 2016
Teva Canada Ltd. will be releasing several batches of generic product, Teva-Divalproex, over the coming weeks.
Apotex Inc. and Health Canada are working to resolve the Apo-Divalproex shortage and more information is expected in the next few weeks regarding availability of this product.
The available supply is being shared across the system. Pharmacists may provide partial refills during this time to help the greatest number of patients maintain access to this important medication.
The availability of generic divalproex sodium is expected to improve over the coming weeks.
Brand name divalproex sodium (Epival) is expected to remain in shortage for several more months. The estimated resupply date for all strengths of Epival is July 22. Based on this estimate, it would reach pharmacies in late July or early August.
December 23, 2015
Currently, pharmaceutical companies are experiencing shortages of divalproex sodium. Generic formulations (including Apotex and Teva) and formulations of Epival (BGP Pharma) are affected. Shortages among generic formulations have been occurring for a longer period of time and the supply of products such as APO-Divalproex may be more depleted/unavailable.
See drugshortages.ca for full details
There is still supply of divalproex sodium available in Ontario.
Some individual pharmacies could be running low but should be able to still source some of this drug. It may require more investigation and pharmacists may need to pursue different avenues.
Distribution centres in Ontario received new shipments of Epival this week.
Teva Canada is estimating some replenishment of 125 mg Teva-Divalproex later this month. Some additional Teva-Divalproex and Epival are expected to be available for release near the end of January.
Apotex's 3 formulations of APO-Divalproex are on back-order for several more months. Apotex's current estimate for resupply is April 30. However, the estimates keey getting pushed back so I don't have great confidence in this date.
December 18, 2015
Canadian pharmaceutical companies are reporting shortages of divalproex sodium (Epival), also known as valproic acid.
As of Thursday December 17, a total of fifteen divalproex sodium shortages were posted on drugshortages.ca by Abbott Laboratories Limited*, Apotex Inc., Pro Doc Limitée, Sanis Health Inc. and Teva Canada Limited. None of the pharmaceutical companies have provided an explanation for the shortages.
This situation is a serious concern. The estimated resupply dates currently range from December 24, 2015 to April 30, 2016. These dates are estimates and could change. Drug shortages, or back-orders, at the level of the pharmaceutical companies do not always result in shortages at community and hospital pharmacies. Although the longer a shortage lasts the greater the likelihood that it could have an impact on patients.
If you or a family member have been prescribed divalproex sodium (Epival), contact your pharmacist and ask about the availability of your medication.
If your pharmacist runs into any difficulty obtaining divalproex sodium they may be able to find some from a different supplier, another drug store, or another chain.
According to the Canadian Pharmacists Association's guide on drug shortages, Step 1 is for pharmacists to exhaust every avenue to supply the medication. This may require looking beyond their regular sources of supply and contacting other wholesalers or calling the manufacturers. Your pharmacist also has access to resources and information through the Ontario Pharmacists Association.
If the situation worsens and your pharmacist is not able to locate any divalproex sodium for you, it is important to work with your pharmacist and your health care provider to manage the drug shortage in the safest way possible.
During a shortage, your pharmacist and health care provider may explore options that could include filling your prescription with a different strength tablet or substituting a different medication. If your dosing instructions change, ensure you understand the instructions and ask questions if it isn't clear.
When a drug is unavailable in Canada, Health Canada's Special Access Program (SAP) will consider requests from health care providers for access to the drug from outside the country. The SAP can be reached 24 hours a day, 365 days a year, and the program strives to process requests within 24 hours of receipt.
It is important to continue to take your medication as indicated. It can be frightening when an epilepsy drug is in short supply but skipping doses, taking less medication, or suddenly stopping an antiseizure drug is dangerous. This can lead to breakthrough seizures, more prolonged seizures or life-threatening events.
Click here for additional information about drug shortages please see our list of frequently asked questions
Click here for additional information about the Health Canada Special Access Program
* This company may be listed on drugshortages.ca incorrectly. Epival is no longer marketed by Abbott Laboratories Limited. According to the Health Canada drug product database, Epival is currently marketed by BGP Pharma. It appears that old drug shortage notifications from 2012 were re-used instead of creating a set of new notifications for the current Epival shortages.